title: [Patogenetic therapy of patients with diabetes mellitus type 2 and cerebral vascular insufficiency].
abstract: Effectiveness of halidor preparation was assessed in a randomized open 8-weeks study in 44 patients with diabetes mellitus type 2 and chronic cerebral blood circulation disorders. A control group included 15 patients with the same pathologies who did not receive halidor. Administration of halidor in doses 100 mg 3 times daily led to the improvement of clinical state in 32 (72,7%) patients that was confirmed by statistically better performance (p<0,05) on the neuropsychological tests: MMSE by 14,7%, clock-drawing test by 16,8%, the Schult test by 23,5%. The blood flow in middle and posterior cerebral arteries was increased by 21 and 23%, respectively (p<0,05), and the vascular tonus was reduced. The possibility of halidor administration to patients with diabetes mellitus with concomitant chronic cerebral blood circulation disorders is discussed.
authors.forename: P R
authors.initials: PR
authors.lastname: Kamchatnov
authors.forename: A V
authors.initials: AV
authors.lastname: Karalkin
authors.forename: A V
authors.initials: AV
authors.lastname: Chugunov
authors.forename: A A
authors.initials: AA
authors.lastname: Kabanov
authors.forename: D A
authors.initials: DA
authors.lastname: Bassé
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhaĭlova
authors.forename: Kh Ia
authors.initials: KhIa
authors.lastname: Umarova
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
mesh_terms: D001537:Bencyclane / Q000008:administration & dosage / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D012307:Risk Factors; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D001537:Bencyclane